A Randomized Trial of High vs Standard Power Radiofrequency Ablation for Pulmonary Vein Isolation: SHORT-AF
- PMID: 37495318
- DOI: 10.1016/j.jacep.2022.12.020
A Randomized Trial of High vs Standard Power Radiofrequency Ablation for Pulmonary Vein Isolation: SHORT-AF
Abstract
Background: High-power, short duration (HPSD) radiofrequency ablation (RFA) is a commonly used strategy for pulmonary vein isolation (PVI).
Objectives: This study sought to compare HPSD with standard power, standard duration (SPSD) RFA in patients undergoing PVI.
Methods: Patients with paroxysmal or persistent (<1 year) atrial fibrillation (AF) were randomized to HPSD (50 W) or SPSD (25-30 W) RFA to achieve PVI. Outcomes assessed included time to achieve PVI (primary), left atrial dwell time, total procedure time, first-pass isolation, PV reconnection with adenosine, procedure complications including asymptomatic cerebral emboli (ACE), and freedom from atrial arrhythmias.
Results: Sixty patients (median age 66 years; 75% male) with paroxysmal (57%) or persistent (43%) AF were randomized to HPSD (n = 29) or SPSD (n = 31). Median time to achieve PVI was shorter with HPSD vs SPSD (87 minutes vs 126 minutes; P = 0.003), as was left atrial dwell time (157 minutes vs 180 minutes; P = 0.04). There were no differences in first-pass isolation (79% vs 76%; P = 0.65) or PV reconnection with adenosine (12% vs 20%; P = 0.26) between groups. At 12 months, recurrent atrial arrhythmias occurred less in the HPSD group compared with the SPSD group (n = 3 of 29 [10%] vs n = 11 of 31 [35%]; HR: 0.26; P = 0.027). There was a trend toward more ACE with HPSD RFA (40% HPSD vs 17% SPSD; P = 0.053).
Conclusions: In patients undergoing AF ablation, HPSD compared with SPSD RFA results in shorter time to achieve PVI, greater freedom from AF at 12 months, and a trend toward increased ACE.
Keywords: ablation; asymptomatic cerebral emboli; atrial fibrillation; high power short duration; pulmonary vein isolation; stroke.
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The study was funded by the Tod Spieker philanthropic fund. Dr Gerstenfeld has served on the advisory board for Biosense Webster and Farapulse, Inc; and received lecture honoraria from Biosense Webster and Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
High Power Short Duration: Is There a Chink in the Armor?JACC Clin Electrophysiol. 2023 Jul;9(7 Pt 2):1048-1050. doi: 10.1016/j.jacep.2023.02.013. Epub 2023 Apr 26. JACC Clin Electrophysiol. 2023. PMID: 37115118 No abstract available.
Similar articles
-
High-power short-duration versus standard-power standard-duration settings for repeat atrial fibrillation ablation.Heart Vessels. 2022 Jun;37(6):1003-1009. doi: 10.1007/s00380-021-01987-9. Epub 2021 Nov 30. Heart Vessels. 2022. PMID: 34846561 Free PMC article.
-
Comparison of clinical and procedural outcomes between high-power short-duration, standard-power standard-duration, and temperature-controlled noncontact force guided ablation for atrial fibrillation.J Cardiovasc Electrophysiol. 2021 Mar;32(3):608-615. doi: 10.1111/jce.14868. Epub 2021 Jan 19. J Cardiovasc Electrophysiol. 2021. PMID: 33415782
-
Pulmonary vein isolation using pulsed field ablation vs. high-power short-duration radiofrequency ablation in paroxysmal atrial fibrillation: efficacy, safety, and long-term follow-up (PRIORI study).Europace. 2024 Jul 2;26(7):euae194. doi: 10.1093/europace/euae194. Europace. 2024. PMID: 38996227 Free PMC article.
-
High-power short duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic review and meta-analysis.Europace. 2021 May 21;23(5):710-721. doi: 10.1093/europace/euaa327. Europace. 2021. PMID: 33523184
-
Meta-analysis of high power short duration in atrial fibrillation ablation - a superior efficient ablation strategy.Acta Cardiol. 2022 Feb;77(1):14-32. doi: 10.1080/00015385.2021.1939512. Epub 2021 Jul 5. Acta Cardiol. 2022. PMID: 34218737 Review.
Cited by
-
Efficacy and safety of high-power short-duration ablation for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.J Interv Card Electrophysiol. 2024 Sep;67(6):1445-1461. doi: 10.1007/s10840-024-01782-2. Epub 2024 Mar 9. J Interv Card Electrophysiol. 2024. PMID: 38460090 Free PMC article.
-
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.J Arrhythm. 2024 Oct 6;40(6):1217-1354. doi: 10.1002/joa3.13082. eCollection 2024 Dec. J Arrhythm. 2024. PMID: 39669937 Free PMC article.
-
Association of a Left Atrial Diverticulum with Adverse Events During Catheter Ablation for Atrial Fibrillation.J Clin Med. 2025 Apr 28;14(9):3041. doi: 10.3390/jcm14093041. J Clin Med. 2025. PMID: 40364073 Free PMC article.
-
High-Power Short-Duration Ablation of Paroxysmal and Persistent Atrial Fibrillation.Rev Cardiovasc Med. 2023 Dec 25;24(12):363. doi: 10.31083/j.rcm2412363. eCollection 2023 Dec. Rev Cardiovasc Med. 2023. PMID: 39077093 Free PMC article. Review.
-
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.J Interv Card Electrophysiol. 2024 Aug;67(5):921-1072. doi: 10.1007/s10840-024-01771-5. J Interv Card Electrophysiol. 2024. Corrected and republished in: Heart Rhythm. 2024 Sep;21(9):e31-e149. doi: 10.1016/j.hrthm.2024.03.017. PMID: 38609733 Corrected and republished.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous